InvestorsHub Logo
Post# of 252545
Next 10
Followers 7
Posts 560
Boards Moderated 0
Alias Born 03/13/2007

Re: rfj1862 post# 50673

Tuesday, 08/07/2007 1:07:08 AM

Tuesday, August 07, 2007 1:07:08 AM

Post# of 252545
>> Not at all. In almost every infected individual there is already a population of virus that is dependent on CXCR4 for entry.

I don't think that's true. In a significant majority of treatment-naive HIV+ patients, most have no CXCR4 tropic virus at all. After CCR5 inhibitor therapy, a small fraction of those who were thought to be CXCR4 tropic negative display CXCR4 tropism fairly rapidly, and it is thought this is due to an insensitive tropism assay. After the first few R4's show up, the rate of R5-->R4 conversion seems to be very slow.

Certainly the mutation from CCR5 to CXCR4 will happen eventually with a CCR5 inhibitor, but apparently the mean time for this to happen is several years if the patient starts out with no CXCR4 tropism.

(I think I've got this right, but if I screwed up somebody will be kind enough to let me know!)

For this reason, and for the reason that mutations render all HIV drugs ineffective eventually, CCR5 inhibitors should become a significant component of HIV therapy.

micro

Life is an IQ test.

email: microcapfun@yahoo.com

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.